Cantargia obtains a granted patent from USPTO concerning IL1RAP in solid tumors
July 15, 2016 02:30 ET
|
Cantargia AB
The United States Patent and Trademark Office (”USPTO”) has granted Cantargia
AB’s (“Cantargia”) patent application concerning IL1RAP as a target molecule for
antibody therapy of several solid tumor...
Opposition inlämnad i Europa mot Cantargias patent avseende leukemi
June 27, 2016 02:30 ET
|
Cantargia AB
Europapatentverket (“EPO”) godkände i oktober 2015 Cantargia AB:s (”Cantargia”)
ansökan avseende IL1RAP som målmolekyl för antikroppsterapi och diagnostik av
leukemi (patentnummer EP2467403). En...
Cantargias produktkandidat CAN04 visar mycket god säkerhet vid höga doser vilket lägger grunden för avslutande GLP-toxicitetsstudie under hösten 2016
June 10, 2016 07:45 ET
|
Cantargia AB
Cantargia AB:s (”Cantargia”) produktkandidat CAN04 genomgår de sista testerna
innan ansökan om kliniska prövningar. Den nyligen genomförda studien studerade
upprepad behandling upp till 100 mg/kg och...
Cantargia’s CAN04 product candidate show very good safety at high dose levels, paving the way for final GLP toxicity study in autumn 2016
June 10, 2016 07:45 ET
|
Cantargia AB
Cantargia AB’s (“Cantargia”) CAN04 product candidate is undergoing the final
tests prior to submission of the application for clinical trials. The recently
completed study investigated repeated...
Cantargia receives Notice of Allowance from USPTO on IL1RAP in solid tumours
June 10, 2016 02:30 ET
|
Cantargia AB
The United States Patent and Trademark Office (“USPTO”) has issued a Notice of
Allowance for Cantargia’s patent application on IL1RAP as target molecule for
antibody therapy of several types of solid...
Cantargia erhåller Notice of Allowance från det amerikanska patentverket kring IL1RAP i solida tumörer
June 10, 2016 02:30 ET
|
Cantargia AB
Det amerikanska patentverket United States Patent and Trademark Office (”USPTO”)
har utfärdat en så kallad Notice of Allowance beträffande Cantargias
patentansökan avseende IL1RAP som målmolekyl för...
Cantargia receives patent approval in Japan for solid tumours
June 08, 2016 06:30 ET
|
Cantargia AB
Cantargia AB’s patent application for IL1RAP as target molecule for antibody
-based therapies and diagnostics of solid tumours has been approved by the Japan
Patent Office (JPO).
The patent approval...
Cantargia erhåller godkänt patent i Japan avseende solida tumörer
June 08, 2016 06:30 ET
|
Cantargia AB
Cantargia AB:s patentansökan avseende IL1RAP som målmolekyl för
antikroppsbaserade terapier samt diagnostik av solida tumörer har godkänts av
Japan Patent Office (JPO).
Patentgodkännandet (patentnr:...
Cantargia receives Notice of Allowance from USPTO on IL1RAP in acute lymphatic leukemia
June 08, 2016 02:30 ET
|
Cantargia AB
The United States Patent and Trademark Office (“USPTO”) has issued a Notice of
Allowance on Cantargia AB’s (“Cantargia”) patent application regarding IL1RAP as
a target molecule for antibody therapy...
Cantargia erhåller Notice of Allowance från det amerikanska patentverket kring IL1RAP i akut lymfatisk leukemi
June 08, 2016 02:30 ET
|
Cantargia AB
Det amerikanska patentverket United States Patent and Trademark Office (”USPTO”)
har utfärdat en så kallad Notice of Allowance för Cantargia AB:s (”Cantargia”)
patentansökan avseende IL1RAP som...